Issue link: https://uberflip.scri.com/i/1531660
0206/25SCR020-1/R3RGB Abstract & Presentation Calendar Tandem Transplantation and Cellular Therapy Meetings 2025 1 Thursday Wednesday Friday Saturday WEDNESDAY, FEBRUARY 12 TH 12:30pm - 5:00pm Honolulu Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 12:30 - 1:30pm Ballroom C Chair Chair Patel K Tandem Wednesday Luncheon Symposium: The Innovation Intersection in B-Cell Cancers: Navigating Choices With Modern Targeted Strategies, Cellular Therapy, and HCT 12:30 - 1:30pm 12:35 - 1:00pm Ballroom C Presenter Masterclass & Case Forum 1 Reshaping Standards of Care in CLL with Targeted and Cellular Therapy Patel K Tandem Wednesday Luncheon Symposium: The Innovation Intersection in B-Cell Cancers: Navigating Choices With Modern Targeted Strategies, Cellular Therapy, and HCT 1:45 - 2:45pm 1:45 - 2:05pm 311 (HCC) Oral 108 Data Management Adjusted Productivity Model within the Sarah Cannon Transplant and Cellular Therapy Network (SCTCTN)- Process and Benefits Zambrano H Zambrano H, Blunk B, Cox T, Culver J, Hatley S, Williams Z (CRPDM) Oral Abstract Presentations 3:15 - 4:45pm 3:30 - 3:45pm 316 ABC Oral 26 Durable Clinical Benefits in Transfusion-Dependent Β-Thalassemia with Exagamglogene Autotemcel Grupp S Frangoul H, Molinari L Oral Abstract - Session M - Gene Therapy, Study Design and Statistics 3:15 - 4:45pm 3:45 - 4:00pm 316 ABC Oral 27 Reni-Cel, an Investigational AsCas12a Gene-Edited Cell Medicine, Led to Sustained Hemoglobin Normalization and Increased Fetal Hemoglobin in Patients with Severe Sickle Cell Disease Treated in the RUBY Trial Walters M Frangoul H Session M - Gene Therapy, Study Design and Statistics 3:30 - 5:30pm 3:45 - 4:00pm 313 ABC Oral 119 Acute Toxicities and Early Outcomes of Tandem Autologous Stem Cell Transplantation in Pediatric High-Risk Neuroblastoma: A Multicenter Study Hudda Z Garcia M (PEDS) Pediatric Best Abstracts 3:15 - 4:45pm 4:00 - 4:15pm 316 ABC Oral 28 Safety and Efficacy of Autologous CD34+ Base Edited Hematopoietic Stem Cells (BEAM-101) for the Treatment of Sickle Cell Disease with Severe Vaso-Occlusive Crises: Results from the Ongoing Phase 1/2 Beacon Study Gupta A Frangoul H Oral Abstract - Session M - Gene Therapy, Study Design and Statistics 3:15 - 4:45pm 4:00 - 4:15pm Ballroom A Oral 10 Risk Factors Associated with Sub-Optimal Outcomes and Hematotoxicity Following Obecabtagene Autoleucel (obe-cel) for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL) Sandhu K Shaughnessy P Oral Abstract - Session A - Leukemia and Relapse 4:15 - 4:30pm Ballroom A Oral 11 CAR and ALL Hematotox Scores Predict Toxicity and Outcomes Among Recipients of Brexucabtagene Autoleucel for R/R ALL in the Real World Outcomes Collaborative of CAR-T in Adult ALL (ROCCA) Consortium Valtis Y Battiwalla M, Majhail N, Malik S, Mathews J, Mountjoy L, Shaughnessy P Oral Abstract - Session A - Leukemia and Relapse